Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.

Tan C, Dannull J, Nair SK, Ding E, Tyler DS, Pruitt SK, Lee WT.

J Surg Res. 2013 Dec;185(2):904-11. doi: 10.1016/j.jss.2013.06.045. Epub 2013 Jul 17.

PMID:
23891424
2.

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.

Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT.

J Transl Med. 2013 Jun 17;11:148. doi: 10.1186/1479-5876-11-148.

3.

Therapeutic immune response induced by electrofusion of dendritic and tumor cells.

Tanaka H, Shimizu K, Hayashi T, Shu S.

Cell Immunol. 2002 Nov;220(1):1-12.

PMID:
12718934
4.

Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.

Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, Koinuma D, Kikuchi T, Tazawa R, Maemondo M, Hagiwara K, Saijo Y, Nukiwa T.

Clin Cancer Res. 2005 Jan 1;11(1):58-66.

6.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.

PMID:
12937899
7.
8.

Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.

Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S.

Dev Biol (Basel). 2004;116:169-78; discussion 179-86.

PMID:
15603192
9.
10.
12.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
13.

Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.

Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT.

Head Neck. 2010 Jun;32(6):700-7. doi: 10.1002/hed.21241.

PMID:
19908319
14.
15.

Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.

Yi H, Guo C, Yu X, Gao P, Qian J, Zuo D, Manjili MH, Fisher PB, Subjeck JR, Wang XY.

Cancer Res. 2011 Nov 1;71(21):6611-20. doi: 10.1158/0008-5472.CAN-11-1801. Epub 2011 Sep 13.

16.

Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O.

Mol Ther. 2002 May;5(5 Pt 1):609-16.

17.

Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.

Jung ID, Shin SJ, Lee MG, Kang TH, Han HD, Lee SJ, Kim WS, Kim HM, Park WS, Kim HW, Yun CH, Lee EK, Wu TC, Park YM.

J Immunol. 2014 Aug 1;193(3):1233-45. doi: 10.4049/jimmunol.1400656. Epub 2014 Jul 2.

18.
19.

[Immunotherapeutic reactivity of dendritic cells loaded with a variety of antigen preparations].

Shimizu K, Kuriyama H, Tamai H, Ueda Y, Yamagishi H, Shu S.

Gan To Kagaku Ryoho. 2004 Oct;31(11):1637-9. Japanese.

PMID:
15553668
20.

Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.

Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.

J Gene Med. 1999 Nov-Dec;1(6):400-6.

PMID:
10753065
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk